Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Recent clinical observations suggest that weight loss from GLP-1 medications may restore ovulatory function in women with polycystic ovary syndrome and obesity-related infertility. This emerging area of research has generated interest among patients planning pregnancy while managing their weight. PlexusDx examines the evidence behind GLP-1 therapy and reproductive health outcomes.
How Weight Loss Affects Female Fertility
Body weight plays a critical role in hormone regulation, particularly for estrogen and insulin signaling pathways that control ovulation. Women with obesity often experience irregular menstrual cycles, anovulation (failure to release eggs), and reduced fertility rates compared to those at healthy weights. Even modest weight reductions of 5-10% can restore normal menstrual function in some women with insulin resistance or PCOS, according to reproductive endocrinology research.
GLP-1 medications like semaglutide work by reducing appetite and improving glucose control, leading to weight loss that may secondarily improve hormonal balance. This mechanism differs from fertility drugs—GLP-1 therapy addresses the underlying metabolic dysfunction rather than directly stimulating ovulation. For women whose infertility stems primarily from obesity-related hormonal disruption, this metabolic correction may naturally restore reproductive capacity.
GLP-1 Medications and Ovulation: The Clinical Evidence
Case reports and observational data have documented instances of spontaneous pregnancy in women using semaglutide or tirzepatide who had previously experienced infertility. However, randomized controlled trials specifically measuring GLP-1 effects on ovulation rates remain limited. Most published outcomes focus on weight loss efficacy rather than fertility metrics, making it difficult to isolate GLP-1's direct reproductive impact from weight loss benefits alone.
A 2023 analysis noted that women with PCOS using GLP-1 receptor agonists experienced improved menstrual regularity alongside weight reduction, though studies did not uniformly measure fertility as a primary endpoint. The medical consensus suggests that any fertility improvement is likely attributable to metabolic improvement and weight loss rather than a direct pharmacologic effect on reproductive organs. Patients considering GLP-1 therapy for fertility concerns should discuss their individual metabolic profile with a reproductive endocrinologist alongside their weight loss provider.
Safety Considerations for GLP-1 During Pregnancy Planning
Current evidence does not support GLP-1 medication use during active pregnancy, and most manufacturers recommend discontinuation before conception. Animal studies have not shown teratogenic effects, but human pregnancy data remains limited because GLP-1 medications are relatively new and were not designed for use in pregnant populations. Women planning pregnancy should discuss timing of GLP-1 therapy with both their reproductive specialist and their weight loss provider.
Discontinuing GLP-1 therapy does not appear to cause rapid weight rebound in all patients, particularly if lifestyle changes and improved metabolic function persist post-therapy. Some women maintain weight loss after stopping GLP-1, while others experience gradual weight regain depending on dietary adherence and activity levels. The decision to continue, pause, or discontinue GLP-1 during fertility treatment should be individualized based on medical history, fertility status, and treatment goals.
Personalized GLP-1 Selection and Genetic Insights for Reproductive Health
PlexusDx offers the Precision Peptide Genetic Test, which identifies individual variations in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—genetic markers linked to peptide pathway responsiveness and weight management outcomes. Women with specific genetic profiles may experience more pronounced weight loss from GLP-1 therapy, potentially improving fertility outcomes faster. This genetic information helps personalize medication selection between semaglutide injection (starting at $149/month) and tirzepatide injection (starting at $249/month) based on individual peptide biology rather than age or weight alone.
PlexusDx maps 14 distinct metabolic pathways and 49 peptide interactions, providing patients and clinicians with granular understanding of how their body processes hunger hormones and glucose regulation. Women planning pregnancy who use compounded semaglutide or tirzepatide from PlexusDx's licensed 503A pharmacies can access this genetic context to optimize their treatment timeline and maximize fertility-relevant metabolic improvements before conception. HSA/FSA eligibility and availability across all 50 states without insurance requirements make personalized GLP-1 therapy accessible for family planning candidates.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can GLP-1 medications directly improve fertility without weight loss?
Current evidence suggests GLP-1 medications improve fertility primarily through weight loss and metabolic improvement rather than direct reproductive effects. The hormone-regulating benefits come from restored insulin sensitivity and reduced inflammation, which secondarily improve ovulation in women with obesity-related infertility.
What does the research say about GLP-1 and pregnancy outcomes?
Published studies on GLP-1 safety during pregnancy remain very limited because these medications were not designed for use in pregnant populations. Manufacturers recommend discontinuation before conception, and most reproductive endocrinologists advise pausing GLP-1 therapy once pregnancy is confirmed or actively being pursued.
How much weight loss is needed to restore ovulation in women with PCOS?
Research suggests that 5-10% weight reduction can restore menstrual regularity and ovulation in women with PCOS and obesity, though individual variation is significant. Some women see improvement with smaller reductions, while others require more substantial weight loss to restore hormonal balance.
Does PlexusDx compounded semaglutide cost more if I'm using it for fertility purposes?
No. PlexusDx compounded semaglutide injection starts at $149/month regardless of dose or indication. Your dose may need to go up, but your price won't—pricing remains flat across three commitment tiers and all doses, with HSA/FSA eligibility available.
How can the Precision Peptide Genetic Test help with fertility-focused weight loss?
The Precision Peptide Genetic Test identifies individual variations in GLP1R, GIPR, FTO, and MC4R that predict how effectively your body will respond to GLP-1 therapy and other peptide-based weight loss approaches. Faster, more sustained weight loss may accelerate fertility improvement, making genetic guidance valuable for women planning pregnancy.
Should I stop GLP-1 therapy if I'm trying to conceive?
Timing depends on your individual situation and should be discussed with both your reproductive endocrinologist and weight loss provider. Some women maintain weight loss after stopping GLP-1, while discontinuing too early may reduce fertility benefits if hormonal improvement is incomplete.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Stop GLP-1 and Not Gain Weight: A Comprehensive Guide
Does Oral Tirzepatide Work as Well as Injections?